Aminoglycoside antibiotics: a new class of drugs leading the market

Business News Agency September 13 hearing: Aminoglycoside antibiotics are antibiotics that have an amino sugar and amino cyclic alcohol structure. They are mainly used clinically for systemic infections caused by sensitive aerobic Gram-negative bacilli, from the 1960s to the 1970s. It has been widely used. In recent years, it has been widely used in clinical applications due to various cephalosporin antibiotics and quinolones antibiotics. At the same time, due to its severe ototoxicity and nephrotoxicity, its application has been limited. However, aminoglycoside antibiotics are still used for the treatment of serious infections caused by aerobic gram-negative bacilli, because PAEs (post-antibiotic effects) of common gram-negative bacilli such as Pseudomonas aeruginosa, Klebsiella pneumophila, and Escherichia coli are long. , such as meningitis, respiratory tract, urinary tract, skin and soft tissue, gastrointestinal tract, burns, trauma and bone and joint infections, etc., have an irreplaceable role in the antibiotic market.

Medication growth is generally equal to antibiotics

Aminoglycosides have a profound impact on the clinical use of antibiotics in China. In China's newly revised medical insurance catalog, almost all commonly used clinical varieties of aminoglycoside antibiotics are included.

Aminoglycoside antibiotics account for about 3% of the total antibiotic market, and constitute the main structure of clinical antibiotic applications with cephalosporins, penicillins, quinolones, and macrolide antibiotics. However, the development of aminoglycoside antibiotics is clearly inferior to that of the carbapenems, which have been rising strongly in the past two years, and the emerging cephalosporins and quinolones. From the perspective of the rate of increase in hospital drug use, aminoglycosides were basically equal to the rate of increase in the use of antibiotics.

In 2009, the amount of aminoglycoside antibiotics used in the national government-run hospital drug market was approximately 1.605 billion yuan, a year-on-year increase of 20%. In 2009, the market growth rate of antibiotics products was approximately 19%.

Independent intellectual property products lead the market

Among the aminoglycoside antibiotics, etimicin was the one with the highest share of drugs. In 2009, the market share exceeded 80%. Etimicin is a new generation of semi-synthetic aminoglycoside antibiotics. It possesses significant advantages such as high efficiency, low toxicity, and resistance to resistant bacteria. It is a class of new antibiotics that have independent intellectual property rights and was developed by Jiangsu Microbiology.

At present, there are 34 production approvals for etimicin, but they are mainly produced by Aida Pharmaceuticals and Hawthorn Pharmaceuticals and their holding companies. In fact, there are not many companies that can produce etimicin in China. Tetracycline stopped production of this drug in 2006 because of the apparent ototoxicity and nephrotoxicity of etimicin.

Isopamicin ranks second in the amount of aminoglycoside antibiotics and entered the hospital statistics in 2006. In 2008, the share of medication reached 16.14%, and the amount of medication used increased rapidly. In contrast, the share of netilmicin's drug use dropped more significantly, from 24.22% in 2005 to 1.53% in 2009.

Isepamicin was marketed in Japan by Toyo Brewery Co., Ltd. in April 1988. At present, only two companies in China, Hisun Pharmaceutical and Hongsheng Pharmaceutical (Haizheng Subsidiary) have obtained production approvals, of which Hongsheng Pharmaceutical's approval was obtained at the end of 2008. The clinical drug use of isepamicin in China is mainly from Japan’s Asahi Chemical Industry Co., Ltd., and the share of imported products was 90% in 2005. After the products of Hisun Pharmaceutical entered the market, the market situation has changed, and the share of imported drugs has decreased year by year. In 2009, it has dropped to around 80%.

Netilmicin has more production companies in China. Drug regulatory authorities have issued 169 production approvals. Zhejiang Aida Pharmaceutical Co., Ltd. has a relatively high production share and a relatively stable market, accounting for about 20% to 30% of the market. In fact, Aida Pharmaceutical also has the highest share in the Etimis market.

Trauma Surgery Series

Distal Femur Locking Plate,Tibial Platform Plates,Tibial Implant Plate,Tibia Locking Plate

Jiangsu Health Medical Technology Development Co., Ltd. , https://www.medicalhos.com

Posted on